Improvement of daratumumab- or elotuzumab-mediated NK cell activity by the bi-specific 4-1BB agonist, DARPin α-FAPx4–1BB: A preclinical study in multiple myeloma
-
Published:2024-07
Issue:
Volume:176
Page:116877
-
ISSN:0753-3322
-
Container-title:Biomedicine & Pharmacotherapy
-
language:en
-
Short-container-title:Biomedicine & Pharmacotherapy
Author:
Saltarella Ilaria,
Link AlexanderORCID,
Lamanuzzi Aurelia,
Reichen ChristianORCID,
Robinson Joanna,
Altamura Concetta,
Melaccio Assunta,
Solimando Antonio Giovanni,
Ria Roberto,
Mariggiò Maria Addolorata,
Vacca Angelo,
Frassanito Maria Antonia,
Desaphy Jean-François